A Proposed National Strategy for Tuberculosis Vaccine Development
The global tuberculosis epidemic causes ∼5% of deaths worldwide. Despite recent concerted and largely successful tuberculosis control efforts, the incidence of tuberculosis in the United States remains 74-fold higher than the stated elimination goal of
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2000-06, Vol.30 (Supplement-3), p.S233-S242 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S242 |
|---|---|
| container_issue | Supplement-3 |
| container_start_page | S233 |
| container_title | Clinical infectious diseases |
| container_volume | 30 |
| creator | Ginsberg, Ann M. |
| description | The global tuberculosis epidemic causes ∼5% of deaths worldwide. Despite recent concerted and largely successful tuberculosis control efforts, the incidence of tuberculosis in the United States remains 74-fold higher than the stated elimination goal of |
| doi_str_mv | 10.1086/313867 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_71231448</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4482229</jstor_id><sourcerecordid>4482229</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-5eb817cd2c6cb7c6e97b4c8abacb42742abb13183e8c1a013fb7c469002a561d3</originalsourceid><addsrcrecordid>eNpN0MtKxDAUBuAginefQKQLcVfNpWnS5TA6jjJ4wStuQpI5lWqnGZNW9O2NdBhdJfB_OZz8CO0RfEywzE8YYTIXK2iTcCbSnBdkNd4xl2kmmdxAWyG8YUyIxHwdbcQngosCb6LBILnxbu4CTJMr3Vau0XVy13rdwut3Ujqf3HcGvO1qF6qQPGprqwaSU_iE2s1n0LQ7aK3UdYDdxbmNHkZn98NxOrk-vxgOJqllBW9TDkYSYafU5tYIm0MhTGalNtqajIqMamMII5KBtERjwsqosrzAmGqekynbRkf93Ll3Hx2EVs2qYKGudQOuC0oQykgWf7uE1rsQPJRq7quZ9t-KYPVblurLivBgMbEzM5j-Y307ERwugA5W16XXja3Cn-OYMv7L9nv2Flrnl3HchVJaxDjt4yq08LWMtX9XcQnB1fj5RU1G2fBpfHOrLtkPEIWIeA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71231448</pqid></control><display><type>article</type><title>A Proposed National Strategy for Tuberculosis Vaccine Development</title><source>MEDLINE</source><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Ginsberg, Ann M.</creator><creatorcontrib>Ginsberg, Ann M.</creatorcontrib><description>The global tuberculosis epidemic causes ∼5% of deaths worldwide. Despite recent concerted and largely successful tuberculosis control efforts, the incidence of tuberculosis in the United States remains 74-fold higher than the stated elimination goal of <1 case per million population by the year 2010. Current bacille Calmette-Guérin vaccines, although efficacious in preventing extrapulmonary tuberculosis in young children, have shown widely variable efficacy in preventing adult pulmonary tuberculosis, confound skin test screening, and are not recommended for use in the United States. The Advisory Council for Elimination of Tuberculosis recently stated that tuberculosis would not be eliminated from the United States without a more effective vaccine. Recent scientific advances have created unprecedented opportunity for tuberculosis vaccine development. Therefore, members of the broad tuberculosis research and control communities have recently created and proposed a national strategy, or blueprint, for tuberculosis vaccine development, which is presented here.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/313867</identifier><identifier>PMID: 10875790</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Adult ; Animal models ; Bacterial diseases ; Bacterial Vaccines - immunology ; BCG Vaccine - immunology ; Biological and medical sciences ; Clinical Trials as Topic - methods ; Epidemiology ; Experimentation ; Health Policy ; Human bacterial diseases ; Humans ; Infections ; Infectious diseases ; International Cooperation ; Medical sciences ; Mycobacterium tuberculosis ; Mycobacterium tuberculosis - immunology ; Tuberculosis ; Tuberculosis and atypical mycobacterial infections ; Tuberculosis control ; Tuberculosis vaccine ; Tuberculosis, Pulmonary - epidemiology ; Tuberculosis, Pulmonary - prevention & control ; United States - epidemiology ; Vaccination</subject><ispartof>Clinical infectious diseases, 2000-06, Vol.30 (Supplement-3), p.S233-S242</ispartof><rights>Copyright 2000 The Infectious Diseases Society of America</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-5eb817cd2c6cb7c6e97b4c8abacb42742abb13183e8c1a013fb7c469002a561d3</citedby><cites>FETCH-LOGICAL-c395t-5eb817cd2c6cb7c6e97b4c8abacb42742abb13183e8c1a013fb7c469002a561d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4482229$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4482229$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,799,23910,23911,25119,27903,27904,57996,58229</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1502350$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10875790$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ginsberg, Ann M.</creatorcontrib><title>A Proposed National Strategy for Tuberculosis Vaccine Development</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><description>The global tuberculosis epidemic causes ∼5% of deaths worldwide. Despite recent concerted and largely successful tuberculosis control efforts, the incidence of tuberculosis in the United States remains 74-fold higher than the stated elimination goal of <1 case per million population by the year 2010. Current bacille Calmette-Guérin vaccines, although efficacious in preventing extrapulmonary tuberculosis in young children, have shown widely variable efficacy in preventing adult pulmonary tuberculosis, confound skin test screening, and are not recommended for use in the United States. The Advisory Council for Elimination of Tuberculosis recently stated that tuberculosis would not be eliminated from the United States without a more effective vaccine. Recent scientific advances have created unprecedented opportunity for tuberculosis vaccine development. Therefore, members of the broad tuberculosis research and control communities have recently created and proposed a national strategy, or blueprint, for tuberculosis vaccine development, which is presented here.</description><subject>Adult</subject><subject>Animal models</subject><subject>Bacterial diseases</subject><subject>Bacterial Vaccines - immunology</subject><subject>BCG Vaccine - immunology</subject><subject>Biological and medical sciences</subject><subject>Clinical Trials as Topic - methods</subject><subject>Epidemiology</subject><subject>Experimentation</subject><subject>Health Policy</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>International Cooperation</subject><subject>Medical sciences</subject><subject>Mycobacterium tuberculosis</subject><subject>Mycobacterium tuberculosis - immunology</subject><subject>Tuberculosis</subject><subject>Tuberculosis and atypical mycobacterial infections</subject><subject>Tuberculosis control</subject><subject>Tuberculosis vaccine</subject><subject>Tuberculosis, Pulmonary - epidemiology</subject><subject>Tuberculosis, Pulmonary - prevention & control</subject><subject>United States - epidemiology</subject><subject>Vaccination</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpN0MtKxDAUBuAginefQKQLcVfNpWnS5TA6jjJ4wStuQpI5lWqnGZNW9O2NdBhdJfB_OZz8CO0RfEywzE8YYTIXK2iTcCbSnBdkNd4xl2kmmdxAWyG8YUyIxHwdbcQngosCb6LBILnxbu4CTJMr3Vau0XVy13rdwut3Ujqf3HcGvO1qF6qQPGprqwaSU_iE2s1n0LQ7aK3UdYDdxbmNHkZn98NxOrk-vxgOJqllBW9TDkYSYafU5tYIm0MhTGalNtqajIqMamMII5KBtERjwsqosrzAmGqekynbRkf93Ll3Hx2EVs2qYKGudQOuC0oQykgWf7uE1rsQPJRq7quZ9t-KYPVblurLivBgMbEzM5j-Y307ERwugA5W16XXja3Cn-OYMv7L9nv2Flrnl3HchVJaxDjt4yq08LWMtX9XcQnB1fj5RU1G2fBpfHOrLtkPEIWIeA</recordid><startdate>20000601</startdate><enddate>20000601</enddate><creator>Ginsberg, Ann M.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20000601</creationdate><title>A Proposed National Strategy for Tuberculosis Vaccine Development</title><author>Ginsberg, Ann M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-5eb817cd2c6cb7c6e97b4c8abacb42742abb13183e8c1a013fb7c469002a561d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Animal models</topic><topic>Bacterial diseases</topic><topic>Bacterial Vaccines - immunology</topic><topic>BCG Vaccine - immunology</topic><topic>Biological and medical sciences</topic><topic>Clinical Trials as Topic - methods</topic><topic>Epidemiology</topic><topic>Experimentation</topic><topic>Health Policy</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>International Cooperation</topic><topic>Medical sciences</topic><topic>Mycobacterium tuberculosis</topic><topic>Mycobacterium tuberculosis - immunology</topic><topic>Tuberculosis</topic><topic>Tuberculosis and atypical mycobacterial infections</topic><topic>Tuberculosis control</topic><topic>Tuberculosis vaccine</topic><topic>Tuberculosis, Pulmonary - epidemiology</topic><topic>Tuberculosis, Pulmonary - prevention & control</topic><topic>United States - epidemiology</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ginsberg, Ann M.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ginsberg, Ann M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Proposed National Strategy for Tuberculosis Vaccine Development</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clinical Infectious Diseases</addtitle><date>2000-06-01</date><risdate>2000</risdate><volume>30</volume><issue>Supplement-3</issue><spage>S233</spage><epage>S242</epage><pages>S233-S242</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>The global tuberculosis epidemic causes ∼5% of deaths worldwide. Despite recent concerted and largely successful tuberculosis control efforts, the incidence of tuberculosis in the United States remains 74-fold higher than the stated elimination goal of <1 case per million population by the year 2010. Current bacille Calmette-Guérin vaccines, although efficacious in preventing extrapulmonary tuberculosis in young children, have shown widely variable efficacy in preventing adult pulmonary tuberculosis, confound skin test screening, and are not recommended for use in the United States. The Advisory Council for Elimination of Tuberculosis recently stated that tuberculosis would not be eliminated from the United States without a more effective vaccine. Recent scientific advances have created unprecedented opportunity for tuberculosis vaccine development. Therefore, members of the broad tuberculosis research and control communities have recently created and proposed a national strategy, or blueprint, for tuberculosis vaccine development, which is presented here.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>10875790</pmid><doi>10.1086/313867</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2000-06, Vol.30 (Supplement-3), p.S233-S242 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71231448 |
| source | MEDLINE; Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Animal models Bacterial diseases Bacterial Vaccines - immunology BCG Vaccine - immunology Biological and medical sciences Clinical Trials as Topic - methods Epidemiology Experimentation Health Policy Human bacterial diseases Humans Infections Infectious diseases International Cooperation Medical sciences Mycobacterium tuberculosis Mycobacterium tuberculosis - immunology Tuberculosis Tuberculosis and atypical mycobacterial infections Tuberculosis control Tuberculosis vaccine Tuberculosis, Pulmonary - epidemiology Tuberculosis, Pulmonary - prevention & control United States - epidemiology Vaccination |
| title | A Proposed National Strategy for Tuberculosis Vaccine Development |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T12%3A48%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Proposed%20National%20Strategy%20for%20Tuberculosis%20Vaccine%20Development&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Ginsberg,%20Ann%20M.&rft.date=2000-06-01&rft.volume=30&rft.issue=Supplement-3&rft.spage=S233&rft.epage=S242&rft.pages=S233-S242&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/313867&rft_dat=%3Cjstor_proqu%3E4482229%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71231448&rft_id=info:pmid/10875790&rft_jstor_id=4482229&rfr_iscdi=true |